Quick Answer
Aptevo Therapeutics Inc. reported Diluted EPS of $87.27 per share (loss) for fiscal year 2025.
Aptevo Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$87.27 | +99.7% |
| 2024 | -$31460.23 | -1257.9% |
| 2023 | -$2316.83 | -147668.8% |
| 2022 | $1.57 | +125.9% |
| 2021 | -$6.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.23 | +99.4% | +73.5% |
| June 30, 2025 | -$8.40 | +99.3% | -91.3% |
| March 31, 2025 | -$4.39 | +98.8% | +98.8% |
| September 30, 2024 | -$357.86 | -1514.9% | +71.1% |
| June 30, 2024 | -$1236.96 | -2192.8% | -235.9% |
| March 31, 2024 | -$368.21 | -2218.6% | -1561.6% |
| September 30, 2023 | -$22.16 | -1377.3% | +58.9% |
| June 30, 2023 | -$53.95 | -1066.8% | -410.4% |
- Aptevo Therapeutics Inc. showed an increase of +99.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Aptevo Therapeutics Inc.’s diluted eps has declined by 1337.7% (from $6.07 per share (loss) to $87.27 per share (loss)).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: